Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06800404 · ClinicalTrials.gov registry record · Phase 2
"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"
A Phase 2 study of Multiple Sclerosis and Relapsing-remitting Multiple Sclerosis (RRMS), sponsored by Hope Biosciences Research Foundation.
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06800404 is a Phase 2 study of Multiple Sclerosis and Relapsing-remitting Multiple Sclerosis (RRMS) that is active but no longer recruiting, run by Hope Biosciences Research Foundation. The registered enrollment target is 10 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06800404, a Phase 2 study of Multiple Sclerosis and Relapsing-remitting Multiple Sclerosis (RRMS), is active but no longer recruiting, sponsored by Hope Biosciences Research Foundation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This protocol is part of a clinical study to evaluate efficacy and safety of multiple intravenous administrations of HB-adMSCs for the treatment of Multiple Sclerosis.
Conditions Studied
Interventions
- DRUG Autologous HB-adMSCs
Study Locations (1)
Texas
- Hope Biosciences Research Foundation - Sugar Land
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-05-02 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06800404
The ClinicalTrials.gov registry entry for NCT06800404 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower). The listed sponsor is Hope Biosciences Research Foundation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Autologous HB-adMSCs is the first listed.
NCT06800404 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06800404 about?
NCT06800404 is a clinical study titled ""HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"". This protocol is part of a clinical study to evaluate efficacy and safety of multiple intravenous administrations of HB-adMSCs for the treatment of Multiple Sclerosis.
What is the current status of trial NCT06800404?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-05-02. Estimated completion is 2027-01.
What conditions does trial NCT06800404 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis (RRMS).
What interventions are being tested in trial NCT06800404?
The interventions under investigation include: Autologous HB-adMSCs (DRUG).
Who is sponsoring clinical trial NCT06800404?
This trial is sponsored by Hope Biosciences Research Foundation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06800404 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RECRUITING · Phase 2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.